Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Expanding Rare Disease Portfolio

summarizeSummary

Neurocrine Biosciences announced a definitive agreement to acquire Soleno Therapeutics for $2.9 billion in cash, significantly expanding its endocrinology and rare disease portfolio with the addition of VYKAT XR.

check_boxKey Events

• Acquisition Agreement

  Neurocrine Biosciences will acquire Soleno Therapeutics for $2.9 billion in an all-cash tender offer, followed by a merger.

• Offer Price

  The offer price is $53.00 per share, representing a 34% premium to Soleno's closing price on April 2, 2026, and a 51% premium to its 30-day volume-weighted average price.

• Strategic Expansion

  The acquisition adds VYKAT XR, a first-in-class FDA-approved treatment for hyperphagia in Prader-Willi syndrome, to Neurocrine's portfolio, strengthening its rare disease and endocrinology focus.

• Financial Impact

  VYKAT XR generated $190 million in 2025 revenue, including $92 million in Q4 2025, providing immediate revenue diversification and growth for Neurocrine.

auto_awesomeAnalysis

This acquisition represents a substantial strategic move for Neurocrine Biosciences, immediately diversifying its commercial portfolio with a third first-in-class medicine. The $2.9 billion all-cash transaction for Soleno Therapeutics, a commercial-stage rare disease company, is funded by cash on hand and modest pre-payable debt, indicating financial strength. The acquired product, VYKAT XR, already generated $190 million in 2025 revenue, providing an immediate boost to Neurocrine's top-line growth and leveraging its existing medical and commercial infrastructure in endocrinology and rare disease. The deal is expected to close within 90 days, subject to regulatory approvals, and is supported by tender and support agreements from Soleno's CEO and former CFO. This move is poised to enhance Neurocrine's long-term revenue growth and value creation, backed by VYKAT XR's strong intellectual property extending into the mid-2040s.